trial

Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

NCTId NCT00100165
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 29 (actual)
Sponsored by University of Colorado, Denver
Primary completion 2007-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
29 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2005-01
Primary completion
2007-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
3-(2,4 dimethoxybenzylidene anabaseine) 150 mg3-(2,4 dimethoxybenzylidene anabaseine) 75 mg

Sponsors

University of Colorado, DenverLead Sponsor
VA Office of Research and DevelopmentCollaborator

Investigators

1
Robert Freedman, MDPrincipal Investigator

Sites

1 total
Denver, United States

Linked catalysts

1
Phase 2 Trial of a Nicotinic Agonist in Schizophrenia — primary completion2007-07

Facts & assertions

4 sourced
Enrollment
29
Phase
PHASE2
Primary Completion Date
2007-07
Status
COMPLETED
relationships
The graph out of here
drug
3-(2,4 dimethoxybenzylidene anabaseine) 150 mg
drug
3-(2,4 dimethoxybenzylidene anabaseine) 75 mg
drug
lead_sponsor
University of Colorado, Denver
company
collaborator
VA Office of Research and Development
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Robert Freedman, MD
person